Intech Biopharm Ltd
Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide… Read more
Intech Biopharm Ltd (6461) - Total Assets
Latest total assets as of September 2025: NT$2.50 Billion TWD
Based on the latest financial reports, Intech Biopharm Ltd (6461) holds total assets worth NT$2.50 Billion TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Intech Biopharm Ltd - Total Assets Trend (2017–2024)
This chart illustrates how Intech Biopharm Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Intech Biopharm Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Intech Biopharm Ltd's total assets of NT$2.50 Billion consist of 17.1% current assets and 82.9% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 8.3% |
| Accounts Receivable | NT$9.28 Million | 0.4% |
| Inventory | NT$63.86 Million | 2.7% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Intech Biopharm Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Intech Biopharm Ltd's current assets represent 17.1% of total assets in 2024, an increase from 7.3% in 2017.
- Cash Position: Cash and equivalents constituted 8.3% of total assets in 2024, up from 4.8% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is inventory at 2.7% of total assets.
Intech Biopharm Ltd Competitors by Total Assets
Key competitors of Intech Biopharm Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Intech Biopharm Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Intech Biopharm Ltd generates 0.02x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Intech Biopharm Ltd is currently not profitable relative to its asset base.
Intech Biopharm Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.28 | 1.31 | 2.65 |
| Quick Ratio | 0.96 | 1.14 | 2.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$116.63 Million | NT$ 112.55 Million | NT$ 255.25 Million |
Intech Biopharm Ltd - Advanced Valuation Insights
This section examines the relationship between Intech Biopharm Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.62 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -11.6% |
| Total Assets | NT$2.40 Billion |
| Market Capitalization | $43.47 Million USD |
Valuation Analysis
Below Book Valuation: The market values Intech Biopharm Ltd's assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Intech Biopharm Ltd's assets decreased by 11.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Intech Biopharm Ltd (2017–2024)
The table below shows the annual total assets of Intech Biopharm Ltd from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$2.40 Billion | -11.63% |
| 2023-12-31 | NT$2.71 Billion | +6.30% |
| 2022-12-31 | NT$2.55 Billion | -1.97% |
| 2021-12-31 | NT$2.60 Billion | -0.76% |
| 2020-12-31 | NT$2.62 Billion | +0.61% |
| 2019-12-31 | NT$2.61 Billion | +3.71% |
| 2018-12-31 | NT$2.51 Billion | +12.03% |
| 2017-12-31 | NT$2.24 Billion | -- |